MMWR Morb Mortal Wkly Rep. 2018 Apr 27;67(16):470-472. doi: 10.15585/mmwr.mm6716a3.
Before the introduction of rotavirus vaccine in 2006, rotavirus was the most common cause of severe diarrhea among U.S. children (1). Currently, two rotavirus vaccines are licensed for use in the United States, both of which have demonstrated good field effectiveness (78%-89%) against moderate to severe rotavirus illness (2), and the use of these vaccines has substantially reduced the prevalence of rotavirus in the United States (3). However, the most recent national vaccine coverage estimates indicate lower full rotavirus vaccine-series completion (73%) compared with receipt of at least 3 doses of vaccines containing diphtheria, tetanus, and pertussis antigens (95%), given on a similar schedule to rotavirus vaccines (4). In the postvaccine era in the United States, rotavirus activity persists in a biennial pattern (3). This report describes three rotavirus outbreaks that occurred in California in 2017. One death was reported; however, the majority of cases were associated with mild to moderate illness, and illness occurred across the age spectrum as well as among vaccinated children. Rotavirus vaccines are designed to mimic the protective effects of natural infection and are most effective against severe rotavirus illness (2). Even in populations with high vaccination coverage, some rotavirus infections and mild to moderate illnesses will occur. Rotavirus vaccination should continue to be emphasized as the best means of reducing disease prevalence in the United States.
在 2006 年轮状病毒疫苗问世之前,轮状病毒是美国儿童严重腹泻的最常见原因(1)。目前,美国有两种轮状病毒疫苗获得许可使用,这两种疫苗均已证明对中度至重度轮状病毒病具有良好的现场效果(78%-89%)(2),并且这些疫苗的使用大大降低了美国轮状病毒的流行率(3)。然而,最近的全国疫苗接种情况估计表明,与至少接种 3 剂含有白喉、破伤风和百日咳抗原的疫苗(95%)相比,完全接种轮状病毒疫苗系列的比例较低(73%),这些疫苗的接种时间与轮状病毒疫苗相似(4)。在美国疫苗接种后时代,轮状病毒活动呈两年一次的模式持续存在(3)。本报告描述了 2017 年加利福尼亚州发生的三起轮状病毒暴发事件。报告了一例死亡病例;然而,大多数病例与轻度至中度疾病有关,疾病发生在全年龄段以及接种过疫苗的儿童中。轮状病毒疫苗旨在模拟自然感染的保护作用,对严重轮状病毒病最有效(2)。即使在疫苗接种覆盖率较高的人群中,也会发生一些轮状病毒感染和轻度至中度疾病。轮状病毒疫苗接种应继续被强调为降低美国疾病流行率的最佳手段。